ROM

E

IPFA/PEI 21st International Workshop on

“Surveillance and Screening of Blood Borne Pathogens”

In collaboration with

the Centro Nazionale Sangue, Istituto Superiore di Sanità (ISS),

and the Italian Society for Transfusion Medicine and Immunohaematology (SIMTI)

21-22 May 2014 Sheraton Roma Hotel, Rome, Italy

DAY ONE Wednesday 21 May 2014

08.30 hrs Session 1 OPENING SESSION • Welcome and introduction • Opening of meeting by Italian official • The Italian blood system: an overview with special focus on plasma production and plasma-derived medicinal products, Dr G. Grazzini (Italian National Blood Centre, Italy) • Transfusion transmissible infections in Italy with special focus on HBV, Dr C. Velati (Italian Society of Transfusion Medicine and Immunohaematology, Italy)

p r o g r a m m e

THIS WORKSHOP IS KINDLY SPONSORED BY:

Abbott · Cerus Corporation · DiaSorin · GFE Blut · GrifolsKedrion · Macopharma · Roche Diagnostics · Terumo BCT · V.I.P.S.

09.15 hrs Session 2 HEPATITIS (KEY NOTE SESSION) • Key-Note: Evolution of Hepatitis and blood safety with special attention to HCV, Dr H. Alter (National Institutes of Health, USA) • HCV inactivation, Dr E. Steinmann (Twincore, Germany) • Treatment of Hepatitis B and C, Prof. J-M. Pawlotsky (French National Reference Center for Viral Hepatitis B, C and delta, France) 10.45 – 11.15 hrs BREAK

11.15 hrs Session 3 ADVANCES IN PATHOGEN REMOVAL / INACTIVATION • Italian research project on PLT pathogen inactivation, Dr P. Rebulla (Foundation Ca’ Granda Ospedale Maggiore Policlinico, Italy) • Prion removal capacity of plasma protein manufacturing Processes: A data collection from PPTA member companies, Dr N. Roth (CSL Behring, USA) • Pathogen inactivation in plasma derivatives, Dr M. Yunoki (Japan Blood Products Organization, Japan)

12.30 – 14.00 hrs LUNCH Kindly sponsored by Terumo BCT

14.00 hrs Session 4 BORDERLINE TRANSFUSION RISKS – UNDERESTIMATED OR OVERESTIMATED? – IMPLICATIONS FOR SAFETY • Human Cytomegalovirus (CMV), Prof. Dr H. Hennig, (Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein, Germany) • HEV update, Prof. R. Tedder (Public Health England, UK) • Malaria screening of donors and donations - issues and outcomes, Dr A. Kitchen (National Blood Service, UK) • Syphilis screening policies around the world, Dr C.A. Akkøk (Oslo University Hospital, Norway)

15.30 – 16.00 hrs BREAK

16.00 hrs Session 5 TESTING ALGORITHMS • Introduction by the moderator: True and false NAT reactive, a donor deferral and re-entry problem?, Dr J. O’Riordan (Irish Blood Transfusion Service, Ireland) • Probability of false initial and repeat ID-NAT reactive donations Dr M. Vermeulen (South African National Blood Service, South Africa) • Confirmatory algorithm for initial reactive MP6 NAT donations in an HBV endemic region, Dr T. Sakuldamrongpanich (Thai Red Cross Society, Thailand) • Impact of multi-dye multiplex PCR technology on testing algorithm, Dr L. Blanco (Centro de Hemoterapia Y Hemodonación de Castilla Y León, Spain)

THIS WORKSHOP IS KINDLY SPONSORED BY:

Abbott · Cerus Corporation · DiaSorin · GFE Blut · GrifolsKedrion · Macopharma · Roche Diagnostics · Terumo BCT · V.I.P.S.

• HBV confirmation of ID and MP6-NAT repeat reactive donations Dr P. Grabarczyk (Institute of Haematology and Transfusion Medicine, Poland) • Panel Discussion – Lead = Dr J. O’Riordan (Irish Blood Transfusion Service, Ireland)

17.45 hrs END OF DAY I

19.00 hrs DEPARTURE FOR DINNER Kindly sponsored by Abbott

DAY TWO: Thursday 22 May 2014

08.30 hrs Session 6 MANUFACTURERS’ SESSION • V.I.P.S. VIPS Mini Pool SD - Virus Inactivation, Ms V. Soulié Indonesian Experience in Producing Minipool Cryoprecipitate, Dr Y. Soedarmono • Abbott Exploring Viral Diversity: HIV, HBV and HTLV in Southern Cameroon, Dr C. Brennan • GFE Blut HIV-1 Multi Target NAT, Prof. K. Roth Update on THERAFLEX UV-Platelets: a novel system for pathogen reduction of platelets, Prof. Dr A. Seltsam • Roche Diagnostics Transform Your Testing Experience, Mr D. DeCan • Grifols Addressing the Potential HEV threat to blood safety, Dr J. Linnen

10.30 – 11.00 hrs BREAK

11.00 hrs Session 7 UPDATE SESSION • WNV, Italian approach, Dr S. Pupella (Istituto Superiore di Sanità, Italy) • WNV, American approach, Dr M. Busch (Blood Systems Research Institute, USA) • Dengue study Brasil, Dr E. Sabino (University of Sao Paulo, Brasil) • vCJD in the UK, Dr P. Bennett (Public Health Directorate, UK)

12.30 – 14.00 hrs LUNCH

THIS WORKSHOP IS KINDLY SPONSORED BY:

Abbott · Cerus Corporation · DiaSorin · GFE Blut · GrifolsKedrion · Macopharma · Roche Diagnostics · Terumo BCT · V.I.P.S.

14.00 hrs Session 8 DONOR POLICY Chair: Margarethe Heiden (Paul-Ehrlich-Institut, Germany) • MSM donor policy: studies from the USA and other countries, Dr B. Custer (Blood Systems Research Institute, USA) • Individual risk assessment in pre-donation screening in Italy, Dr B. Suligoi (Istituto Superiore di Sanità, Italy) • MSM and HIV in the Netherlands: Arguments for ban? Prof. Dr H. Zaaijer (Sanquin-BOI, The Netherlands) • Round table 15.30 hrs SUMMARY

16.00 hrs CLOSURE OF THE MEETING

16.15 hrs FAREWELL DRINKS

THIS WORKSHOP IS KINDLY SPONSORED BY:

Abbott · Cerus Corporation · DiaSorin · GFE Blut · GrifolsKedrion · Macopharma · Roche Diagnostics · Terumo BCT · V.I.P.S.